# Robert P Hebbel

List of Publications by Year
in descending order



| 105 | 10,351 | 57758 44 | 46799 89 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 107 | 107 | 107 | 7485 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease. Blood, 2021, 137, 1538-1549. | 1.4 | 35 |
| 2 | Multiple inducers of endothelial <scp>NOS</scp> (<scp>eNOS</scp>) dysfunction in sickle cell disease. American Journal of Hematology, 2021, 96, 1505-1517. | 4.1 | 7 |
| 3 | Relationship of Circulating Endothelial Cells With Obesity and Cardiometabolic Risk Factors in Children and Adolescents. Journal of the American Heart Association, 2021, 10, e018092. | 3.7 | 9 |
| 4 | Abnormal Endothelial Gene Expression Associated With Early Coronary Atherosclerosis. Journal of the American Heart Association, 2020, 9, e016134. | 3.7 | 21 |
| 5 | Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus Expressing Interferon-Î² in Preclinical Models of Non-Small Cell Lung Cancer. Translational Oncology, 2020, 13, 100782. | 3.7 | 14 |
| 6 | Reproducibility of endothelial microparticles in children and adolescents. Biomarkers in Medicine, 2020, 14, 43-51. | 1.4 | 3 |
| 7 | Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. Frontiers in Immunology, 2020, 11, 613278. | 4.8 | 20 |
| 8 | The multifaceted role of ischemia/reperfusion in sickle cell anemia. Journal of Clinical Investigation, 2020, 130, 1062-1072. | 8.2 | 48 |
| 9 | SARS-CoV-2 severity in African Americans â€“ A role for Duffy Null?. Haematologica, 2020, 105, 2892. | 3.5 | 7 |
| 10 | Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A. Blood, 2020, 136, 30-31. | 1.4 | 1 |
| 11 | Blood outgrowth endothelial cells overexpressing eNOS mitigate pulmonary hypertension in rats: a unique carrier cell enabling autologous cell-based gene therapy. Translational Research, 2019, 210, 1-7. | 5.0 | 6 |
| 12 | Morphine promotes neovascularizing retinopathy in sickle transgeneic mice. Blood Advances, 2019, 3, 1073-1083. | 5.2 | 7 |
| 13 | Sickle hemoglobin oxygen affinityâ€shifting strategies have unequal cerebrovascular risks. American Journal of Hematology, 2018, 93, 321-325. | 4.1 | 42 |
| 14 | Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot study. Vascular Health and Risk Management, 2018, Volume 14, 205-211. | 2.3 | 2 |
| 15 | The missing middle of sickle therapeutics: Multiâ€agent therapy, targeting risk, using biomarkers. American Journal of Hematology, 2018, 93, 1439-1443. | 4.1 | 3 |
| 16 | Pathobiology of Sickle Cell Disease. , 2018, , 571-583. | | 5 |
| 17 | A monocyteâ€TNFâ€endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade. American Journal of Hematology, 2017, 92, 1119-1130. | 4.1 | 23 |
| 18 | Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Research and Treatment, 2017, 166, 541-547. | 2.5 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Blood endothelial cells: utility from ambiguity. Journal of Clinical Investigation, 2017, 127, 1613-1615. | 8.2 | 32 |
| 20 | Microparticles in sickle cell anaemia: promise and pitfalls. British Journal of Haematology, 2016, 174, 16-29. | 2.5 | 50 |
| 21 | Reproducibility of circulating endothelial cell enumeration and activation in children and adolescents. Biomarkers in Medicine, 2016, 10, 463-471. | 1.4 | 8 |
| 22 | Sickle cell disease: renal manifestations and mechanisms. Nature Reviews Nephrology, 2015, 11, 161-171. | 9.6 | 258 |
| 23 | H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice. Frontiers in Pharmacology, 2014, 5, 79. | 3.5 | 32 |
| 24 | Ischemia-reperfusion Injury in Sickle Cell Anemia. Hematology/Oncology Clinics of North America, 2014, 28, 181-198. | 2.2 | 111 |
| 25 | Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood, 2014, 123, 377-390. | 1.4 | 555 |
| 26 | Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood, 2014, 123, 1747-1756. | 1.4 | 98 |
| 27 | Interference With TNFÎ± Using Long-Term Etanercept In S+SAntilles Sickle Transgenic Mice Ameliorates Abnormal Endothelial Activation, Vasoocclusion, and Pulmonary Hypertension Including Its Pulmonary Arterial Wall Remodeling. Blood, 2013, 122, 728-728. | 1.4 | 6 |
| 28 | Carbon-Fiber Microelectrode Amperometry Reveals Sickle-Cell-Induced Inflammation and Chronic Morphine Effects on Single Mast Cells. ACS Chemical Biology, 2012, 7, 543-551. | 3.4 | 18 |
| 29 | Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness. British Journal of Haematology, 2012, 156, 535-544. | 2.5 | 77 |
| 30 | Selective Enhancement of Contractions to Î±1-adrenergic Receptor Activation in the Aorta of Mice With Sickle Cell Disease. Journal of Cardiovascular Pharmacology, 2011, 57, 263-266. | 1.9 | 5 |
| 31 | Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. Blood, 2011, 117, 4125-4133. | 1.4 | 52 |
| 32 | Reconstructing sickle cell disease: A dataâ€based analysis of the â€œhyperhemolysis paradigmâ€•for pulmonary hypertension from the perspective of evidenceâ€based medicine. American Journal of Hematology, 2011, 86, 123-154. | 4.1 | 139 |
| 33 | Regional and systemic hemodynamic responses following the creation of a murine arteriovenous fistula. American Journal of Physiology - Renal Physiology, 2011, 301, F845-F851. | 2.7 | 21 |
| 34 | Morphine Stimulates Wound Healing Via Mu Opioid Receptor and Promotes Wound Closure in Sickle Mice. Blood, 2011, 118, 2118-2118. | 1.4 | 2 |
| 35 | Plasma Hemoglobin and Heme Trigger Weibel Palade Body Exocytosis and Vaso-Occlusion in Transgenic Sickle Mice. Blood, 2011, 118, 896-896. | 1.4 | 7 |
| 36 | Carbon Monoxide Therapy Modulates Hematopoietic Stem Cell Development in Heme-Oxygenase-1 Knockout Mice. Blood, 2011, 118, 1318-1318. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse. American Journal of Hematology, 2010, 85, 41-45. | 4.1 | 39 |
| 38 | The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood, 2010, 115, 2483-2490. | 1.4 | 76 |
| 39 | Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood, 2010, 116, 456-465. | 1.4 | 159 |
| 40 | Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood, 2010, 116, 687-692. | 1.4 | 187 |
| 41 | Circulating Activated Endothelial Cells in Pediatric Obesity. Journal of Pediatrics, 2010, 157, 547-551. | 1.8 | 26 |
| 42 | Nuclear factor-kappa B (NFÎºB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease. Translational Research, 2010, 155, 170-177. | 5.0 | 40 |
| 43 | Exhaled Carbon Monoxide as a Marker of Hemolysis In Transgenic Mouse Models of Sickle Cell Anemia.. Blood, 2010, 116, 1642-1642. | 1.4 | 0 |
| 44 | Association of Non-Healing Wounds, Pain and Neurochemical Alterations In Sickle Cell Disease. Blood, 2010, 116, 842-842. | 1.4 | 0 |
| 45 | Carbon Monoxide Therapy Reduces Reactive Oxygen Species Production and the Short-Term Hematopoietic Stem Cell Population In Heme-Oxygenase-1 Knockout Mice. Blood, 2010, 116, 4767-4767. | 1.4 | 0 |
| 46 | A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis. Cardiovascular & Hematological Disorders Drug Targets, 2009, 9, 271-292. | 0.7 | 78 |
| 47 | The systems biologyâ€based argument for taking a bold step in chemoprophylaxis of sickle vasculopathy. American Journal of Hematology, 2009, 84, 543-545. | 4.1 | 15 |
| 48 | Cannabinoids as Analgesics for Pain in Sickle Cell Disease.. Blood, 2009, 114, 822-822. | 1.4 | 0 |
| 49 | Genetic endothelial systems biology of sickle stroke risk. Blood, 2008, 111, 3872-3879. | 1.4 | 54 |
| 50 | Association of Inflammatory Transcription Factors in Human Blood Outgrowth Endothelial Cells and Development of Stroke in Sickle Cell Disease. FASEB Journal, 2008, 22, 43-43. | 0.5 | 0 |
| 51 | Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6061-6065. | 7.1 | 25 |
| 52 | Sickle Cell Disease Endothelial Activation and Dysfunction. , 2007, , 1352-1359. | | 0 |
| 53 | Cleaved Kininogen Inhibits Capillary Tube Formation by Circulating Endothelial Cells via inhibiting matrix metalloproteaseâ€2 (MMPâ€2). FASEB Journal, 2007, 21, A194. | 0.5 | 0 |
| 54 | Anomalous Renal Effects of Tin Protoporphyrin in a Murine Model of Sickle Cell Disease. American Journal of Pathology, 2006, 169, 21-31. | 3.8 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Robust Vascular Protective Effect of Hydroxamic Acid Derivatives in a Sickle Mouse Model of Inflammation. Microcirculation, 2006, 13, 489-497. | 1.8 | 19 |
| 56 | Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radical Biology and Medicine, 2006, 40, 1443-1453. | 2.9 | 79 |
| 57 | Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radical Biology and Medicine, 2006, 41, 1771-1780. | 2.9 | 126 |
| 58 | Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. Journal of Clinical Investigation, 2006, 116, 808-816. | 8.2 | 233 |
| 59 | Hypoxia/Reoxygenation Induced Blood Cell Adhesion in Cerebral Venules of Sickle Cell Transgenic (Î² S ) Mice: The Two Faces of eNOS. FASEB Journal, 2006, 20, LB22. | 0.5 | 0 |
| 60 | Farnesoid X Receptor Dependent Regulation of MMP9 in Blood Outgrowth Endothelial Cells. FASEB Journal, 2006, 20, . | 0.5 | 0 |
| 61 | Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. Translational Research, 2005, 145, 204-211. | 2.3 | 39 |
| 62 | Circulating endothelial cells. Thrombosis and Haemostasis, 2005, 93, 228-235. | 3.4 | 337 |
| 63 | Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H2715-H2725. | 3.2 | 142 |
| 64 | Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB Journal, 2005, 19, 989-991. | 0.5 | 115 |
| 65 | Transgenic Sickle Mice Are Markedly Sensitive to Renal Ischemia-Reperfusion Injury. American Journal of Pathology, 2005, 166, 963-972. | 3.8 | 108 |
| 66 | Oxidative Stress and Vaso-Occlusion in Sickle Cell Disease: Role of Activated Leukocytes and Redox Active Iron.. Blood, 2005, 106, 3165-3165. | 1.4 | 3 |
| 67 | Genetic Influence on the Systems Biology of Sickle Stroke Risk Detected by Endothelial Gene Expression.. Blood, 2005, 106, 73-73. | 1.4 | 3 |
| 68 | Therapeutic Inhibition of Endothelial Cell Tissue Factor Expression In Vivo by Nitric Oxide and Arginine in Sickle Transgenic Mice.. Blood, 2005, 106, 210-210. | 1.4 | 0 |
| 69 | Phenotypic Correction of von Willebrand Disease Type 3 Blood-Derived Endothelial Cells with Lentiviral Vectors Expressing von Willebrand Factor.. Blood, 2005, 106, 5522-5522. | 1.4 | 0 |
| 70 | The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy. Microcirculation, 2004, 11, 129-151. | 1.8 | 305 |
| 71 | Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H293-H301. | 3.2 | 107 |
| 72 | The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy. Microcirculation, 2004, 11, 129-151. | 1.8 | 321 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Microvascular blood flow and stasis in transgenic sickle mice: Utility of a dorsal skin fold chamber for intravital microscopy. American Journal of Hematology, 2004, 77, 117-125. | 4.1 | 67 |
| 74 | Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood, 2004, 104, 840-846. | 1.4 | 180 |
| 75 | Blood Outgrowth Endothelial Cells (BOEC) Contribute to Tumor Vascularization and Can Be Used for Delivery of Cancer Gene Therapy.. Blood, 2004, 104, 3173-3173. | 1.4 | 8 |
| 76 | Special issue of Microcirculation: examination of the vascular pathobiology of sickle cell anemia. Foreword. Microcirculation, 2004, 11, 99-100. | 1.8 | 14 |
| 77 | The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation, 2004, 11, 129-51. | 1.8 | 183 |
| 78 | Sickle blood contains tissue factorâ€“positive microparticles derived from endothelial cells and monocytes. Blood, 2003, 102, 2678-2683. | 1.4 | 483 |
| 79 | Sickle hemoglobin instability: a mechanism for malarial protection. Redox Report, 2003, 8, 238-240. | 4.5 | 19 |
| 80 | Transgenic sickle mice have vascular inflammation. Blood, 2003, 101, 3953-3959. | 1.4 | 195 |
| 81 | Oxidative Stress and Induction of Heme Oxygenase-1 in the Kidney in Sickle Cell Disease. American Journal of Pathology, 2001, 158, 893-903. | 3.8 | 177 |
| 82 | NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. American Journal of Physiology - Cell Physiology, 2001, 281, C1422-C1433. | 4.6 | 112 |
| 83 | Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood, 2001, 97, 1937-1941. | 1.4 | 146 |
| 84 | Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of Clinical Investigation, 2000, 105, 71-77. | 8.2 | 1,370 |
| 85 | Desferrioxamine (DFO) conjugated with starch decreases NAD redox potential of intact red blood cells (RBC): Evidence for DFO as an extracellular inducer of oxidant stress in RBC. American Journal of Hematology, 2000, 65, 281-284. | 4.1 | 4 |
| 86 | Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320. | 1.4 | 198 |
| 87 | Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood, 2000, 96, 2451-2459. | 1.4 | 301 |
| 88 | Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320. | 1.4 | 10 |
| 89 | Sickle Cell Anemia as a Possible State of Enhanced Anti-Apoptotic Tone: Survival Effect of Vascular Endothelial Growth Factor on Circulating and Unanchored Endothelial Cells. Blood, 1999, 93, 3824-3830. | 1.4 | 113 |
| 90 | Transport of <sup>14</sup>Câ€deferiprone in normal, thalassaemic and sickle red blood cells. British Journal of Haematology, 1999, 105, 1081-1083. | 2.5 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis, 1999, 3, 147-158. | 7.2 | 138 |
| 92 | Comparative Oxidation of Hemoglobins A and S. Blood, 1998, 91, 3467-3470. | 1.4 | 66 |
| 93 | Comparative Oxidation of Hemoglobins A and S. Blood, 1998, 91, 3467-3470. | 1.4 | 0 |
| 94 | A Novel Technique for Culture of Human Dermal Microvascular Endothelial Cells under either Serum-Free or Serum-Supplemented Conditions: Isolation by Panning and Stimulation with Vascular Endothelial Growth Factor. Experimental Cell Research, 1997, 230, 244-251. | 2.6 | 77 |
| 95 | Circulating Activated Endothelial Cells in Sickle Cell Anemia. New England Journal of Medicine, 1997, 337, 1584-1590. | 27.0 | 593 |
| 96 | Inhibition of Sickle Erythrocyte Adhesion to Immobilized Thrombospondin by von Willebrand Factor Under Dynamic Flow Conditions. Blood, 1997, 89, 2560-2567. | 1.4 | 40 |
| 97 | CD36-positive stress reticulocytosis in sicle cell anemia. Translational Research, 1996, 127, 340-347. | 2.3 | 44 |
| 98 | Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. , 1996, 51, 296-301. | | 83 |
| 99 | Multiple mechanisms of sickle erythrocyte adherence to vascular endothelial cells. Clinical Hemorheology and Microcirculation, 1992, 12, 185-189. | 1.7 | 1 |
| 100 | Unique promotion of erythrophagocytosis by malondialdehyde. American Journal of Hematology, 1988, 29, 222-225. | 4.1 | 18 |
| 101 | Erythrocyte (Ca+2+Mg+2)-ATPase activity: Increased sensitivity to oxidative stress in glucose-6-phosphate dehydrogenase deficiency. American Journal of Hematology, 1985, 19, 131-136. | 4.1 | 11 |
| 102 | Clinical diversity of sickle cell anemia: Genetic and cellular modulation of disease severity. American Journal of Hematology, 1983, 14, 405-416. | 4.1 | 71 |
| 103 | Abnormal Adherence of Sickle Erythrocytes to Cultured Vascular Endothelium. Journal of Clinical Investigation, 1980, 65, 154-160. | 8.2 | 388 |
| 104 | Erythrocyte Adherence to Endothelium in Sickle-Cell Anemia. New England Journal of Medicine, 1980, 302, 992-995. | 27.0 | 498 |
| 105 | Blood Endothelial Cells. , 0, , 1612-1620. | | 0 |